Literature DB >> 10626743

Analysis of post-transplant immune status in recipients of liver/bone marrow allografts.

M A Chatzipetrou1, J M Mathew, N S Kenyon, V Esquenazi, J Miller, C Ricordi, A G Tzakis.   

Abstract

The aims of this study were to assess the effect of donor bone marrow infusion on the reactivity of recipient peripheral blood lymphocytes (PBL) to mitogen and to donor and third-party cells after primary liver allotransplantation and to identify any correlation between altered immunoreactivity and HLA mismatches, occurrence of rejection, and immunosuppression. The immunoreactivity of recipient PBL toward frozen donor splenocytes was evaluated in mixed lymphocyte culture (MLC) (n = 29) and cell-mediated lympholysis (CML) (n = 27) assays in time intervals ranging from 0.7 to 27 months after transplant. Overall, the mean anti-donor MLC stimulation index (SI) fell from 25.6 +/- 5.2 preoperatively to 4.8 +/- 1.7 after transplantation (p < 0.002), with 14 out of 29 (48.3%) patients developing donor-specific MLC hyporeactivity. HLA class II mismatches were significantly associated with recipient post-transplant immune profile (p < 0.05): MLC donor specific hyporesponsiveness was observed in 70%, versus 37% of patients who shared a class II antigen, versus those that did not. Of the control group, 61.1% developed donor-specific nonreactivity versus 27.2% in the donor bone marrow cells (DBMC) group (p = 0.02). Donor-specific CML hyporeactivity was observed after transplantation, independent of DBMC infusion, with mean percentage values of pre- and post-transplant donor-specific lysis of 22.4% +/- 4.1% versus 3.1% +/- 1.6%, p = 0.0004, respectively. Our results suggest that DBMC infusion favors development of nonspecific MLC hyporesponsiveness to donor and third-party alloantigen, with maintenance of reactivity to mitogen and no additional effect on T-cell cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626743     DOI: 10.1016/s0198-8859(99)00115-9

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

Review 1.  Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes.

Authors:  Carmen Fotino; Camillo Ricordi; Vincenzo Lauriola; Rodolfo Alejandro; Antonello Pileggi
Journal:  Rev Diabet Stud       Date:  2010-08-10

Review 2.  Microchimerism in promoting graft acceptance in clinical transplantation.

Authors:  James M Mathew; Joseph R Leventhal; Joshua Miller
Journal:  Curr Opin Organ Transplant       Date:  2011-08       Impact factor: 2.640

3.  Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.

Authors:  Josh Levitsky; James M Mathew; Michael Abecassis; Anat Tambur; Joseph Leventhal; Dhivya Chandrasekaran; Nancy Herrera; Patrice Al-Saden; Lorenzo Gallon; Anmaar Abdul-Nabi; Guang-Yu Yang; Sunil M Kurian; Daniel R Salomon; Joshua Miller
Journal:  Hepatology       Date:  2012-07-17       Impact factor: 17.425

4.  Immune "tolerance profiles" in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays.

Authors:  James M Mathew; Gaetano Ciancio; George W Burke; Rolando O Garcia-Morales; Anne Rosen; Edward Wang; Carmen I Gomez; Bonnie B Blomberg; Laphalle Fuller; Violet Esquenazi; Camillo Ricordi; Joshua Miller
Journal:  Hum Immunol       Date:  2010-03-11       Impact factor: 2.850

5.  Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation.

Authors:  Josh Levitsky; Sumeet K Asrani; Thomas Schiano; Adyr Moss; Kenneth Chavin; Charles Miller; Kexin Guo; Lihui Zhao; Manoj Kandpal; Nancy Bridges; Merideth Brown; Brian Armstrong; Sunil Kurian; Anthony J Demetris; Michael Abecassis
Journal:  Am J Transplant       Date:  2020-05-25       Impact factor: 8.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.